All In Biotech

NDA 020297 · Waylis Therap

Coreg

Carvedilol · Oral · alpha-Adrenergic Blocker; beta-Adrenergic Blocker

Novel

Last checked: Nov 20, 2026Latest source record: Jul 26, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1995

Sep 14, 1995

Approved uses

7

Original approval plus efficacy supplements

Registered trials

238

43 Phase 3, 25 recruiting

FAERS reports

136,140

94,757 serious, 16,459 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 31, 2026.

1. INDICATIONS AND USAGE COREG is an alpha-/beta-adrenergic blocking agent indicated for the treatment of: mild to severe chronic heart failure ( 1.1 ) left ventricular dysfunction following myocardial infarction in clinically stable patients ( 1.2 ) hypertension ( 1.3 ) 1.1 Heart Failure COREG is indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ACE inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization [see Drug Interactions (7.4) , Clinical Studies (14.1) ]. 1.2 Left Ventricular Dysfunction following Myocardial Infarction COREG is indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40% (with or without symptomatic heart failure) [see Clinical Studies (14.2) ]. 1.3 Hypertension COREG is indicated for the management of essential hypertension [see Clinical Studies (14.3 , 14.4) ]. It can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [see Drug Interactions (7.2) ].

Mechanism: COREG is a racemic mixture in which nonselective β-adrenoreceptor blocking activity is present in the S(-) enantiomer and α1-adrenergic blocking activity is present in both R(+) and S(-) enantiomers at equal potency. COREG has no intrinsic sympathomimetic activity.

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • COREG · CARVEDILOL 12.5MG · TABLET, ORAL · Prescription · TE AB
  • COREG · CARVEDILOL 6.25MG · TABLET, ORAL · Prescription · TE AB
  • COREG · CARVEDILOL 25MG · TABLET, ORAL · Prescription · TE AB
  • COREG · CARVEDILOL 3.125MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Carvedilol" as an intervention, any sponsor and status, largest first.

All 238 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue9,046
  • dyspnoea8,485
  • diarrhoea7,248
  • dizziness7,052
  • nausea6,781
  • drug ineffective5,941
  • death5,882
  • hypotension5,755
  • asthenia5,512
  • off label use4,744
  • acute kidney injury4,527
  • fall4,508

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,227
20051,652
20062,062
20072,497
20082,214
20092,734
20103,387
20114,256
20124,744
20134,238
20147,329
20158,726
201610,195
20179,778
201810,884
201910,340
20208,835
20218,114
20227,236
20237,051
20246,870
20256,725
20265,045

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Coreg (Carvedilol)

2024 spending

$1.0M

Beneficiaries

248

689 claims

Per beneficiary

$4,179

$12.18 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$25,889
2024$1,036,298

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 804 on PubMed

Sponsor: Waylis Therap

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.